Novartis takes global rights to Abogen's in vivo mRNA T-cell engager ABO2203
Illustration (decorative, not data).Summary
ABO2203 is not an in vivo CAR-T. It uses lipid nanoparticles to deliver mRNA encoding a CD19×CD3 T-cell engager, so that the patient's own cells “manufacture” the bispecific to clear B cells. It is in a Phase 1 study in refractory autoimmune disease; the first data made public cover 3 patients with refractory secondary immune thrombocytopenia. Novartis also receives an exclusive option on next-generation assets from Abogen's mRNA/LNP platform. Notably, a $575 million upfront is high for an early Phase 1 asset, suggesting big pharma is willing to bet early on “biologics generated in vivo”, and that mRNA companies have found a new outlet beyond vaccines in autoimmunity.
Deal terms, as disclosed
$575M upfront + up to ~$7.2B in milestones (including all option exercises) + sales royalties.
Summary of public disclosures, not investment advice. Amounts are as announced; milestone payments are contingent and may never be paid.
Related same deal type
- Simcere Zaiming licenses CD79a×CD19×CD3 trispecific SIM0660 to RocheSep 2026
- Haisco immunology asset goes into ARCH-founded NewCo SentiveraAug 2026
- J&J locks up Sail Biomedicines' in vivo CAR-T with an equity stake and an acquisition optionJul 2026
- GemPharmatech and Humlab partner on global distribution of humanized mouse modelsJul 2026
Asset owners and investors: write to bd@inlightbio.com. Newsletter and report questions: contact@inlightbio.com.